Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 15/20 | 0.45 |
| ▸ | RARG | P13631 | 15/20 | 0.45 |
| ▸ | RARA | P10276 | 15/20 | 0.45 |
| ▸ | RXRA | P19793 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27332310 | 0.78 | RARB (0.46) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL6428471 | 0.77 | RARB (0.38) | RARBRARGRARARXRACXCR5 | |
| SCHEMBL9187716 | 0.76 | RARG (0.56) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL27332311 | 0.76 | RARB (0.46) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL8322245 | 0.73 | RARB (0.52) | RARBRARGRARACYP3A4KMT2A | |
| SCHEMBL9188789 | 0.73 | RARB (0.47) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL7224462 | 0.73 | RARB (0.57) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL27324962 | 0.72 | RARB (0.66) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL10567353 | 0.71 | RARB (0.47) | RARBRARGRARARXRACYP3A4 | |
| SCHEMBL2910869 | 0.70 | RARB (0.59) | RARBRARGRARARXRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0682516-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994017796-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |